NEJM evidence 2022 Jun 01
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
ABSTRACT
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin. Median overall survival (95% Cl) was 12.8 (11.1-14.0) months in the durvalumab group. Rates of grade 3 or 4 adverse events were similar between groups.
Related Questions
When using hypofractionated RT (i.e., 67.5 Gy in 15 fractions), can chemotherapy be delivered concurrently?
Options for systemic therapy in NCC...
New answer by Radiation Oncologist at University of Alabama at Birmingham (May 17, 2024)
Our institutional approach depends on the initial risk for widespread disease.
In patients who would otherwise be potentially cured with surgery (i.e., localized intrahepatic...
Was this monitored in TOPAZ-1?
New comment by ( September 5, 2024)
I feel that ctDNA certainly can serve as a response parameter in following biliary tract cancers. In patients who do not have elevated CEA or CA19-9 on presentation, ctDNA cer...